Visualitza per autor "Longo-Muñoz, Federico"
Ara mostrant els elements 1-4 d 4
-
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
Muñoz, Andrés; Jiménez-Castro, Jerónimo; Jimenez-Fonseca, Paula; Pericay, Carles; Longo-Muñoz, Federico; Argilés Martinez, Guillem; García-Alfonso, Pilar (MDPI, 2021-09-08) -
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
Fudio, Salvador; Tabernero Caturla, Josep; Chawla, Sant P.; Longo-Muñoz, Federico; Subbiah, Vivek; Moreno, Victor (Springer, 2021-01) -
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
Shitara, Kohei; Doi, Toshihiko; Hosaka, Hisashi; Santoro, Armando; Longo-Muñoz, Federico; Alsina Maqueda, Maria; Thuss-Patience, Peter (Springer, 2022-05) -
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
Longo-Muñoz, Federico; Castellano, D.; Alexandre, Jerome; Chawla, Sant P.; Fernández, Cristian; Kahatt, Carmen; Sanz Garcia, Enrique (Elsevier, 2022-09)